New EBV vaccines enter human safety trials

NCT ID NCT06908096

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 7 times

Summary

This study tests two experimental vaccines against Epstein-Barr virus (EBV), which causes mono and is linked to cancers. Researchers will give 750 healthy adults aged 18-29 three shots over several months to check for side effects and immune response. The goal is to find a safe vaccine that could prevent EBV infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EBV gH/gL/gp42-ferritin nanoparticle vaccine with or without gp350-ferritin, both with ALFQ adjuvant
What this could lead to: If successful, this could lead to a vaccine that prevents Epstein-Barr virus infection and its complications, like mono and certain cancers.
What could go wrong: This is an early Phase 1 trial focused on safety, so it's too soon to know if the vaccines will work. Side effects are possible, and the results may not lead to a licensed vaccine.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection infectious mononucleosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV EPSTEIN-BARR VIRUS INFECTION INFECTIOUS MONONUCLEOSIS MONO

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.